DrugPatentWatch Database Preview
RYTARY Drug Profile
When do Rytary patents expire, and when can generic versions of Rytary launch?
Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has thirty-seven patent family members in fourteen countries.
The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
Summary for RYTARY
| International Patents: | 37 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 3 |
| Patent Applications: | 32 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RYTARY |
| Drug Sales Revenues: | Drug sales revenues for RYTARY |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RYTARY |
| DailyMed Link: | RYTARY at DailyMed |
Recent Litigation for RYTARY
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| IMPAX LABORATORIES, INC. v. ZYDUS PHARMACEUTICALS USA, INC. | 2017-12-21 |
| IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. | 2015-09-17 |
Pharmacology for RYTARY
| Drug Class | Aromatic Amino Acid |
Synonyms for RYTARY
| (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid |
| 500019-90-9 |
| 57308-51-7 |
| AC1L2XHE |
| Carbidopa / Levodopa |
| CARBIDOPA AND LEVODOPA |
| Carbidopa Levodopa |
| Carbidopa mixture with Levodopa |
| Carbidopa-L-dopa mixt |
| Carbidopa-L-dopa mixt. |
| Carbidopa-levodopa (1:10) |
| Carbidopa-levodopa ER |
| Carbidopa-levodopa extended release |
| Carbidopa-levodopa mixt |
| Carbidopa-levodopa mixt. |
| carbidopa, levodopa drug combination |
| CHF 1512 |
| Co-careldopa |
| CR-3 |
| CR-5 |
| DM-1992 |
| Dopabain |
| Duodopa |
| Duopa |
| IPX 066 |
| IPX066 |
| Isicom |
| IVTMXOXVAHXCHI-YXLMWLKOSA-N |
| L-Tyrosine, 3-hydroxy-, mixt. with (S)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid |
| L-Tyrosine, 3-hydroxy-, mixt. with (S)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid (10:1) |
| Levodopa / carbidopa |
| levodopa carbidopa |
| Levodopa-carbidopa (10:1) |
| Levodopa/Carbidopa Solution |
| LS-158296 |
| Nacom |
| Nakom |
| ND 0612 |
| ND0612 |
| SCHEMBL2049245 |
| Sinemet CR |
| Sinemet CR4 |
Paragraph IV (Patent) Challenges for RYTARY
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| RYTARY | CAPSULE, EXTENDED RELEASE;ORAL | carbidopa; levodopa | 203312 | 2015-06-24 |
| RYTARY | CAPSULE, EXTENDED RELEASE;ORAL | carbidopa; levodopa | 203312 | 2015-06-10 |
US Patents and Regulatory Information for RYTARY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-004 | Jan 7, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-004 | Jan 7, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-004 | Jan 7, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-001 | Jan 7, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RYTARY
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007016679 | Start Trial |
| Canada | 2711014 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2006073729 | Start Trial |
| South Korea | 20100099731 | Start Trial |
| European Patent Office | 2234963 | Start Trial |
| Israel | 206756 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
